FDA Drug Safety Review Will Consider Pros And Cons Of Separate Safety Agency
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency is in discussions with the Institute of Medicine to initiate a study on the effectiveness of the drug safety system, particularly in the post-marketing phase. The IoM study is the centerpiece of an FDA drug safety initiative, announced Nov. 5, that packages together ongoing projects.